Email updates

Keep up to date with the latest news and content from BMC Neurology and BioMed Central.

Open Access Research article

Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers

Delicias Muñoz1, Antonio Escartín2, Dolores Dapena3, Francisco Coret4, Dionisio Fernández-Uría5, Domingo Pérez6, Bonaventura Casanova7*, Cristina Guijarro-Castro8, Elvira Munteis9, María del-Campo Amigo10, Robustiano Pego11, Carmen Calles12, César García-Rey13, Nuria Monsalve14 and David Sánchez-Matienzo14

Author Affiliations

1 Department of Neurology, Hospital Xeral-Cies, Pontevedra, Spain

2 Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

3 Department of Neurology, Hospital Universitario de Santiago, Santiago de Compostela, A Coruña, Spain

4 Department of Neurology, Hospital Clínico, Valencia, Spain

5 Department of Neurology, Hospital de Cabueñes, Gijón, Asturias, Spain

6 Department of Neurology, Hospital del Bierzo, Ponferrada, León, Spain

7 Department of Neurology, Hospital Universitario y Politécnico La Fe, Valencia, 46026, Spain

8 Department of Neurology, Hospital Doce de Octubre, Madrid, Spain

9 Department of Neurology, Hospital del Mar, Barcelona, Spain

10 Department of Neurology, Hospital de Pontevedra, Pontevedra, Spain

11 Department of Neurology, Hospital Lucus Augusti, Lugo, Spain

12 Department of Neurology, Hospital Universitari Son Espases, Palma de Mallorca, Spain

13 Medical Adviser, Medical Writing, Madrid, Spain

14 Medical Department, Merck, S.L., Madrid, Spain

For all author emails, please log on.

BMC Neurology 2013, 13:82  doi:10.1186/1471-2377-13-82

Published: 11 July 2013

Abstract

Background

This study aimed to correlate body mass index or biomarkers with the frequency of common adverse events (AEs) with subcutaneous IFN β-1a during treatment titration in patients with relapsing-remitting multiple sclerosis previously naïve to IFN β.

Methods

Eighty-four patients (66.3% females) were followed up during 8 weeks, 25.3% were overweight and 14.5% were obese.

Results

Biomarkers steadily increased during all study period by 45.3% for β2-microglobulin, 262.8% for olygoadenylate synthetase-1, and 92.8% for neopterin. Overall AE reporting did not vary with the dose or treatment duration.

Conclusions

BMI was not predictive of increased risk for AEs. Biomarkers did not discriminate on the frequency of any AE either.

Keywords:
Interferon β-1a; Body mass index; Biomarkers; β2-microglobulin; OAS; Neopterin; Adverse events